Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
103Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.82M | $71.18M | $1.34 |
| 2024 | $0.00 | $-63.73M | $-1.55 |
| 2023 | $3.50M | $-54.19M | $-2.53 |
| 2022 | $1.41M | $-39.70M | $-5.53 |
| 2021 | $3.00M | $-84.94M | $-21.50 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.14 per share
Typical surprise +31.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.35 vs $-0.23miss
- Wed, May 13$-0.30 vs $-0.33beat
- Tue, Mar 17$-0.34 vs $-0.35beat
- Wed, Nov 12$-0.10 vs $-0.27beat
- Mon, Aug 11$1.71 vs $-0.39beat
- Wed, May 14$-0.24 vs $-0.35beat
Estimates and results for ABEO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.98
- Implied price
- $7.90
- Return from $5.99
- 5.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.93 — -34.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 0 | 2 | 4 | 6 | 8 |
|---|---|---|---|---|---|
| -2.0% | — | -16.5% | -4.1% | 4.0% | 10.2% |
| 3.0% | — | -12.2% | 0.8% | 9.3% | 15.8% |
| 8.0% | — | -8.0% | 5.7% | 14.6% | 21.4% |
| 13.0% | — | -3.7% | 10.6% | 19.9% | 27.1% |
| 18.0% | — | 0.5% | 15.5% | 25.3% | 32.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (3)
- Newsseekingalpha.com·2d ago·Positive
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·2d ago·Neutral
Abeona Therapeutics Q2 Earnings Call Highlights Abeona Therapeutics NASDAQ: ABEO reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that affected revenue recognition.
View source ↗ - Newsglobenewswire.com·2d ago·Negative
…6.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 – CLEVELAND, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2026 and provided an update on commercial execution for ZEVASKYN (prademagene zamikeracel). Commercial Update Steady launch-year growth for ZEVASKYN.
View source ↗